LBA20 First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
| Autor: | Kok, M., Voorthuis, R.A.B., De Boo, L., van Rossum, A.G.J., Mandjes, I., Balduzzi, S., Chelushkin, M., Rosenberg, E.H., Horlings, H.M., Loo, C.E., Heijns, J.B., Agterhof, M., De Valk, B., Riel, A-M.V., Van Der Velden, A., Dercksen, M., Imholz, A., van Leeuwen-Stok, A.E., Oosterkamp, H.M., Linn, S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S1213-S1213 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|